Introduction {#Sec1}
============

Optimal development of the endometrium is an essential prerequisite for successful blastocyst implantation. Progesterone (P) is essential for secretory differentiation of endometrium, and the need for oestrogen in cooperation with P in regulating the implantation process is species-specific \[[@CR1]\]. Our current knowledge of the cellular and molecular events orchestrating endometrial growth and differentiation prior to implantation is limited.

In the natural cycle, the human endometrium is receptive during a short period, approximately 19 to 24 days after the onset of menstruation \[[@CR2]--[@CR6]\]. Prior to and during this period, the endometrium undergoes extensive morphological and physiological changes to facilitate implantation of the embryo \[[@CR2], [@CR6], [@CR7]\]. These changes are tightly controlled by oestrogen and P \[[@CR6], [@CR8], [@CR9]\]. The responsiveness of the endometrium to P is partly dependent upon the pre-ovulatory changes that have occurred under the influence of oestrogen. This is illustrated by the fact that high oestrogen levels and/or prolonged oestrogen exposure accelerates endometrial maturation, thus disturbing the synchrony of embryo and endometrial development and subsequent implantation \[[@CR10], [@CR11]\]. Currently, there is no clear definition and understanding of human endometrial maturation and only limited knowledge about the cellular mechanisms involved. We define mature endometrial tissue as the physiological state of the human endometrium that allows a correct response to the luteal P, resulting in implantation of the embryo and maintenance of pregnancy.

Our limited understanding of the processes underlying endometrial maturation and P-controlled differentiation prior to and during implantation is largely due to the lack of relevant model systems to evaluate endometrial responses under physiologically relevant conditions. Previous work has demonstrated that explant culture of human endometrial tissue is a suitable model to study the response to oestrogen and P, most likely due to the preservation of the tissue context \[[@CR12]--[@CR14]\]. Using this model we showed previously that the responsiveness of the endometrium to oestrogen changes throughout the proliferative phase with regard to the regulation of gene expression and proliferation \[[@CR12]\].

The present study was designed to gain more insight into the responses of human endometrium to P with regard to gene expression and into the influence of 17β-oestradiol (17β-E~2~) on this process. To this end, global gene expression analysis was performed on human endometrial tissue fragments collected from the menstrual and late proliferative phases after short-term culture in the presence of P and 17β-E~2~.

Materials and methods {#Sec2}
=====================

**Human endometrial tissue.** Endometrial tissue was collected from 26 women (20--45 years of age) with regular menstrual cycles who underwent surgery for benign indications. The tissue was collected from hysterectomy specimens for benign indications or by pipelle biopsies during laparoscopy for sterilisation (Pipelle catheter, Unimar Inc., Prodimed, Neuilly-Enthelle, France). It was documented that the women were not on any kind of steroid medication. All women who agreed to participate in the study signed an informed consent form according to a protocol approved by the Medical Ethical Committee of the Academic Hospital Maastricht. Tissue was transported to the laboratory in DMEM/Ham's F12 medium on ice. A portion of each sample was fixed in 10% buffered formalin for evaluation by histology. The endometrium was dated according to clinical information with respect to the start of the last menstrual period, which was reconfirmed by histological examination of the tissue \[[@CR15]\]. Of the 26 biopsy specimens, 11 were collected in the proliferative phase \[menstrual phase, cycle day (CD)1--5, *n*=6; late proliferative phase, CD11--14, *n*=5\], and 15 were collected in the secretory phase \[early secretory (ES), CD15--18, *n*=7; mid-secretory (MS), CD19--24, *n*=8\]. Of the 11 biopsy specimens collected from the proliferative phase, 4 were used for microarray studies, and 7 were used for validation purposes with real-time PCR analysis. The biopsy specimens collected from the secretory phase were used for validation only.

**Explant cultures.** Human endometrium explant cultures were prepared from menstrual phase and late proliferative phase endometrium as described by Punyadeera et al. \[[@CR16]\]. In brief, human endometrial tissue was cut into 2--3 mm^3^ pieces. A total of 24 explants were placed in Millicell-CM culture inserts (0.4 µm pore size, 30 mm diameter; Millipore, France) in 6-well plates containing 1.2 ml phenol red-free DMEM/Ham's F12 medium (Life Technologies, Grand Island, NY), supplemented with L-glutamine (1%), penicillin and streptomycin (1%, P/S). Cultures were performed for 24 h. Previous experiments have shown that collagenase activity remains very low in proliferative endometrial tissue during the first 24 h of culture \[[@CR17]\] and that the tissue viability is not affected after 24 h of culture \[[@CR13]\].

The explants prepared from late proliferative phase endometrium were cultured in the presence of vehicle (0.1% ethanol), 17β-E~2~ and P (1 nM each), or P alone (1 nM). The 17β-E~2~ was included to maintain the *in vivo* oestrogen support. In order to make inferences with regard to the responsiveness of the endometrium before and after prolonged *in vivo* oestrogen exposure, we also treated explant cultures prepared from menstrual phase endometrium (CD3 and CD4) with 17β-E~2~ and P. To test the importance of 17β-E~2~ in the response of late proliferative phase endometrium to P, 17β-E~2~ was also omitted from some cultures. The steroid hormones were provided by Organon N.V. (Oss, The Netherlands).

**Total RNA extraction and cDNA synthesis.** Total cellular RNA from explants was extracted using the SV total RNA isolation kit (Promega, USA) according to the manufacturer's protocol, with slight modifications: The concentration of DNase-1 during DNase treatment of the RNA samples was doubled, and the incubation time was extended by 15 min in order to completely remove genomic DNA. Total RNA was eluted from the column in 50 µl RNase-free water and stored at −70°C until further analysis. The quality of the RNA samples was determined with the Agilent bioanalyzer 2100 lab-on-a-chip (Agilent, USA). All the samples analysed gave 28S to 18S ratios higher than 1.5. PCR for a housekeeping gene, GAPDH, was performed to confirm that the RNA samples were free of genomic DNA.

Total RNA (1 µg) was incubated with random hexamers (1 µg/µl, Promega) at 70°C for 10 min. The samples were chilled on ice for 5 min. To this mixture, a reverse transcriptase (RT) mix consisting of 5× RT buffer (4 µl), 10 mM dNTP mix (1 µl; Pharmacia, Uppsala, Sweden), 0.1 M DTT (2 µl; Invitrogen, CA, USA), and superscript II reverse transcriptase (200 U/µl; Invitrogen) was added, and the samples were incubated at 42°C for 1 h, after which the reverse transcriptase was inactivated by heating the samples at 95°C for 5 min. The cDNA was stored at −20°C until further use. In each real-time PCR reaction, 50 ng cDNA template was used.

**Affymetrix gene chip microarrays**. Pooling of the RNA samples was performed according to the phase of the menstrual cycle and treatment conditions, *i.e.* two RNA samples from the menstrual phase (CD3 and CD4) and two RNA samples from the late proliferative phase (CD12 and CD13) were pooled. cRNA was generated from the pooled RNA and was labelled with biotin according to the Affymetrix protocol (Santa Clara, USA). cDNA was hybridised to the Affymetrix HU-133A chips, which contains approximately 22 000 human oligonucleotide probe sets, including 68 controls. The chip hybridisations were carried out in triplicate. After washing, the chips were scanned and analysed using the MicroArray suite MAS5. A detail description of the Affymetrix chip content is available at the NetAffy analysis web page (http://www.affymetrix.com/analysis/index.affx).

**Microarray data analysis.** Following gene chip data quality control, data files (.EXP, .DAT, .CEL) generated by MAS5 were transferred by FTP to the server housing the Rosetta Resolver Gene Expression Data Analysis System. Rosetta Resolver uses Affymetrix gene chip error models to transform the raw data into a processed form that can be used in various expression analyses and allows normalization of sample data of triplicate hybridizations using one-way analysis of variance (ANOVA) \[[@CR18]\]. Changes in expression levels between the control and the treated samples were calculated using two criteria: (1) the absolute fold change (\>2-fold) (*e.g.* the ratio between treated and control samples) and (2) a corresponding *p*-value less than 0.01.

The use of microarrays results in a massive amount of data, which requires special tools to filter and extract relevant information. By combining the fold changes or log ratios and the *p*-value, we generated a so-called significance code, which simplifies the selection and extraction of genes of interest, especially when analyzing various conditions. The significance code assigned to the genes was based on ANOVA-retrieved *p*-values and up- or down-regulation compared to the untreated samples. A significance code of 1 (increased or up-regulated) was used for genes with *p*\<0.01 and a log ratio \>0; a significance code of −1 (decreased or down-regulated) was used for genes with *p*\<0.01 and log ratio \<0. For genes that didn't show significant regulation, the significance code was 0 (log ratio =0 and *p*\>0.01 independent of log ratio).

Data were then exported from Rosetta Resolver to the Spotfire decision site 7.1 (Spotfire,Göteborg, Sweden), in which gene sets of interest were visualized and subsequently selected. Data were analyzed through the use of Ingenuity Pathways Analysis (IPA, Ingenuity® Systems, www.ingenuity.com). The data set containing the significantly up- and down-regulated genes and the corresponding expression values were uploaded into the application. Each gene identifier was mapped to its corresponding gene object in the Ingenuity Pathways Knowledge Base. These genes, called focus genes, were overlaid onto a global molecular network developed from information contained in the Ingenuity Pathways Knowledge Base. Networks of these focus genes were then algorithmically generated based on their connectivity.

A network is a graphical representation of the molecular relationships between gene products. The gene products are represented as nodes, and the biological relationship between two nodes is represented as a line. All lines are supported by at least one reference in literature, textbook, or canonical information stored in the Ingenuity Pathways Knowledge Base. The intensity of the node colour indicates the degree of up- (red) or down- (green) regulation. Nodes are displayed using various shapes that represent the functional class of the gene product.

**Validation of array data using real-time PCR analysis.** A selection of genes was validated with q-PCR to confirm expression in the samples used for microarray analysis. In addition, the expression of these genes was evaluated in an independent series of experiments. To confirm that the genes induced by P *in vitro* are indeed up-regulated during the implantation window, we also assessed their expression levels in endometrial tissue collected in the ES and MS phases of the cycle.

Primers and probes were purchased from Perkin-Elmer Applied Biosystems as pre-developed assays. Human cyclophilin A was selected as an endogenous RNA control in order to normalize for differences in the amount of total RNA added to each reaction. Uncultured human endometrial tissue was included as a positive control. All PCR reactions were performed using an ABI Prism 7700 sequence detection system (Perkin-Elmer Applied Biosystems). The thermal cycling conditions comprised an initial decontamination step at 50°C for 2 min, a denaturation step at 958C for 10 min, and 40 cycles of 15 s at 95°C, followed by 1 min at 60°C. Experiments were performed for each sample in duplicate. Quantitative values were obtained from the threshold cycle number (Ct), at which the increase in the signal associated with exponential growth of PCR products was first detected with the ABI Prism 7700 sequence detector software (Perkin-Elmer, Foster city, CA) The fold-change in expression was calculated using the δδ Ct method, with cyclophilin A mRNA as an internal control \[[@CR19]\]. For a detailed description of the procedure, please refer to the ABI user manual (http://www.uk1.unifreiburg.de/core/facility/tagman/user_bulletin_2.pdf).

**Statistical analysis of real-time PCR results.** Statistical tests were carried out using the SPSS 11 (SPSS Inc., Chicago, IL) statistical analysis package. The effects of 17β-E~2~+P and P alone on cultured explants were analysed using the nonparametric paired Wilcoxon signed rank test at a confidence level of 95%. The nonparametric unpaired Mann-Whitney U test at a confidence level of 95% was employed to analyse the real-time PCR data generated from uncultured ES phase endometrial tissue and uncultured MS phase endometrial tissue.

Results {#Sec3}
=======

**Validation of array data with quantitative real-time PCR.** Eight genes were selected from the initial dataset on the basis of fold-change (≥2-fold) and on literature-documented expression during the implantation window: (1) four genes previously described in literature to be up-regulated during the implantation window and selectively stimulated by 17β-E~2~+P in late proliferative phase but not menstrual phase endometrium (Dickkopf homolog 1, DDK1; thrombomodulin, THBD; monoamine oxidase A, MAOA; gastrin, GAS) \[[@CR2], [@CR20], [@CR21]\]; (2) two genes not yet reported that were selectively stimulated by 17β-E~2~+P in late proliferative phase explants but not in menstrual phase explants (cytidine deaminase, CDA; SPARC-like 1, SPARCL1); and (3) two genes that were selectively stimulated by 17β-E~2~+P in menstrual phase explants but not in late proliferative phase explants (trefoil factor 1, TFF1; mammaglobin 1).

The real-time PCR results corroborated well with the array data (Table [1](#Tab1){ref-type="table"}). We performed additional independent experiments to validate the observed effects of treatment with 17β-E~2~+P and P alone (Fig. [Fig1](#Fig1){ref-type="fig"}). From the validated genes, DKK1, MAOA and SPARCL1 were significantly stimulated by P in late proliferative and menstrual phase explants both in the presence and absence of 17β-E~2~. The induction of SPARCL1 expression by P was significantly decreased in the presence of 17β-E~2~ in both menstrual and late proliferative phase explants. Table 1Validation results of the microarray findings for selected genes.GeneReal-time PCR individual samplesPooled array samplesE~2~+PM phaseE~2~+PLP phaseP aloneM phaseP aloneLP phaseE~2~+PE~2~+PP aloneCD3CD4CD12CD13CD3CD4CD12CD13M phaseLP phaseLP phaseDKK11.801.932.6712.683.202.964.2713.691.586.035.01THBD1.111.142.724.082.243.592.673.481.302.952.43MAOA0.971.195.641.851.821.806.361.191.102.592.00GAS0.690.261.073.071.510.571.952.491.002.191.58CDA1.270.621.974.011.091.341.023.610.322.821.86SPARCL11.472.436.963.021.111.874.072.361.292.002.04Gene transcript levels of DKK1, THBD, MAOA, GAS, CDA and SPARCL1 were assessed with quantitative real-time PCR in the individual samples used for microarray hybridization. Data are presented as fold change \[P, progresterone; E~2~, 17/gb-oestradiol; CD, cycle day; M, menstrual (*n*=2); LP, late proliferative (*n*=2)\].Figure 1Mean fold changes found for DKK1, THBD, MAOA, GAS, CDA and SPARCL1 in menstrual phase (M, *n*=4) and late proliferative phase (LP, *n*=3) explants treated with 17β-oestradiol and progesterone (17β-E~2~+P, dark grey bars) or P alone (light grey bars). Controls (open bars) were cultured with vehicle alone. Data are presented as fold changes (\**p*\<0.05).

The response of DKK1 to P was higher in the late proliferative phase explants than in the menstrual phase explants, whereas the induction of mammaglobin expression by 17β-E~2~+P and P alone was more pronounced in menstrual phase than in late proliferative phase endometrium. Thrombomodulin expression was induced only by P in late proliferative phase explants.

The expression of DKK1, THBD, MAOA, GAS, CDA and SPARCL1 was also assessed in an independent series of ES and MS endometrial samples to confirm selective up-regulation in the implantation window. The expression levels are presented in Fig. [2](#Fig2){ref-type="fig"}. The expression of DKK1, MAOA, CDA and SPARCL1 was significantly higher in MS endometrium compared to ES endometrium. Figure 2.Example of a highly significant network identified in the gene expression profile of menstrual phase endometrium treated with 17β-oestradiol and progesterone (17β-E~2~+P) as determined by the Ingenuity Pathways Analysis program.

**Gene expression in menstrual and late proliferative phase endometrial tissue explants after 17β-E**~2~**+P or P treatment.** Treatment of late proliferative phase endometrial tissue with 17β-E~2~+P up-regulated (≥2-fold) the expression of 110 gene transcripts and down-regulated (≥2-fold) the expression of 109 gene transcripts when compared to the control (vehicle) (Table [2](#Tab2){ref-type="table"}). Treating late proliferative phase explants with P alone up-regulated (≥2-fold) the expression of 107 gene transcripts and down-regulated (≥2-fold) the expression of 54 gene transcripts when compared to the control (vehicle) (Table [3](#Tab3){ref-type="table"}). A total of 77/107 up-regulated and 42/54 down-regulated genes were also modulated by 17β-E~2~+P treatment in late proliferative phase explants (Table [3](#Tab3){ref-type="table"}). Table 2Genes affected by 17β-oestradiol and progesterone (17/gb−E2+P) in explants of late proliferative phase endometrium.GeneGene Symbolfold changeAccession \#Functioncytochrome P450, family 26, subfamily A, polypeptide 1CYP26A133.11NM_000783.1metabolismhemoglobin, alpha 2--28.18V00489--calpain 6CAPN619.05NM_014289.2metabolismheart and neural crest derivatives expressed 2HAND210.47NM_021973.1transcription factorsecretoglobin, family 1D, member 2SCGB1D210.00NM_006551.2extracellular matrixhemoglobin, alpha 1HBA19.55AF105974.1transportFK506 binding protein 5FKBP57.76NM_004117.1metabolismchemokine (C-X-C motif) ligand 11CXCL117.59AF030514.1signal transductioncarbohydrate (N-acetylglucosamine 6-O) sulfotransferase 7CHST77.08NM_019886.1metabolismglycine-N-acyltransferaseGLYAT6.17AW024233metabolismhemoglobin, betaHBB6.17M25079.1transportdickkopf homolog 1 (Xenopus laevis)DKK16.03NM_012242.1growth factorHomo sapiens mutant beta-globin (HBB) gene, complete cds.--5.50AF059180--neuronal pentraxin IINPTX25.50U26662.1cell adhesionPDZ domain containing 3PDZK35.50AF338650.1signal transductionapolipoprotein DAPOD4.90NM_001647.1transportalkaline phosphatase, placental (Regan isozyme)ALPP4.79NM_001632.2metabolismkeratin 6AKRT6A4.68J00269.1structural proteinG protein-coupled receptor 105GPR1054.47NM_014879.1signal transductionsolute carrier family 7, member 8SLC7A84.37NM_012244.1transporthypothetical protein FLJ11539FLJ115394.17NM_024748.1--a disintegrin-like and metalloprotease with thrombospondin type 1 mtif, 8ADAMTS83.98NM_007037.1cell growthintegrin, beta-like 1ITGBL13.80NM_004791.1cell adhesionpotassium inwardly-rectifying channel, subfamily J, member 8KCNJ83.80NM_004982.1transportRGC32 proteinRGC323.80NM_014059.1cell growthprostaglandin-endoperoxide synthase 1PTGS13.72NM_000962.1metabolismregulator of G-protein signalling 2, 24kDaRGS23.72NM_002923.1signal transductioncannabinoid receptor 1 (brain)CNR13.55U73304signal transductionhemoglobin, deltaHBD3.39NM_000519.2transportkeratin 6BKRT6B3.39L42612.1structural proteinsushi-repeat-containing protein, X-linkedSRPX3.24NM_006307.1cell adhesionthrombomodulinTHBD3.24NM_000361.1membrane proteindelta sleep inducing peptide, immunoreactorDSIPI3.16AL110191.1transcription factorcytochrome P450, family 4, subfamily B, polypeptide 1CYP4B13.09J02871.1metabolismhemoglobin, gamma AHBG13.09NM_000559.1transportpaired basic amino acid cleaving system 4PACE43.09NM_002570.1signal transductioninsulin receptor substrate 2IRS23.02BF700086signal transductionmetallothionein 1KMT1K2.95R06655transportamylase, alpha 1A; salivaryAMY1A2.88NM_004038.1metabolismfibrinogen-like 2FGL22.88NM_006682.1extracellular matrixlatent transforming growth factor beta binding protein 1LTBP12.88NM_000627.1protein bindingmonoamine oxidase AMAOA2.88NM_000240.1transportretinol binding protein 4, plasmaRBP42.88NM_006744.2transportcytidine deaminaseCDA2.82NM_001785.1metabolismpotassium voltage-gated channel, subfamily G, member 1KCNG12.82AI332979transportmitogen-activated protein kinase kinase 6MAP2K62.82NM_002758.1signal transductionsolute carrier family 15 (H+/peptide transporter), member 2SLC15A22.82BF223679transporthemoglobin, gamma GHBG22.75AI133353transportprotein kinase, X-linkedPRKX2.75NM_005044.1metabolismsuppressor of cytokine signaling 1SOCS12.75AB005043.1signal transductionKIAA0924 proteinKIAA09242.69NM_014897.1nuclearsecretoglobin, family 1D, member 1SCGB1D12.69NM_006552.1extracellular matrixserine (or cysteine) proteinase inhibitor, clade E, member 1SERPINE12.69NM_000602.1metabolismchloride channel 4CLCN42.63AA071195transportfatty-acid-Coenzyme A ligase, long-chain 2FACL22.63NM_001995.1metabolismmonoamine oxidase BMAOB2.63NM_000898.1transportsecretoglobin, family 2A, member 1SCGB2A12.63NM_002407.1hormone bindingATPase, H+ transporting, lysosomal 70kDa, V1 subunit AATP6V1A2.57NM_001690.1transportdipeptidylpeptidase 4DPP42.57M80536.1metabolismnuclear factor I/BNFIB2.57AI186739transcription factorcreatine kinase, brainCKB2.51NM_001823.1metabolismcytokine receptor-like factor 1CRLF12.51NM_004750.1signal transductioniroquois homeobox protein 4IRX42.51NM_016358.1transcription factorHomo sapiens mRNA; cDNA DKFZp586B0220--2.45AL049435.1--chemokine (C-X-C motif) ligand 10CXCL102.45NM_001565.1signal transductionhypothetical protein FLJ20701FLJ207012.45NM_017933.1--insulin-like growth factor binding protein 1IGFBP12.45NM_000596.1signal transductionNorrie disease (pseudoglioma)NDP2.45NM_000266.1signal transductionzinc finger protein 145ZNF1452.45NM_006006.1protein bindinghypothetical protein FLJ20366FLJ203662.40NM_017786.1--peroxisome proliferative activated receptor, gamma, coactivator 1PPARGC12.40NM_013261.1DNA bindingS100 calcium binding protein A2S100A22.40NM_005978.2transportArg/Abl-interacting protein ArgBP2ARGBP22.34NM_021069.1structural proteininterleukin 1 receptor-like 1IL1RL12.34NM_003856.1signal transductionNPD009 proteinNPD0092.34AF237813.1--Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2CITED22.29NM_006079.1transcription factorcolony stimulating factor 2 receptor, alpha, low-affinityCSF2RA2.29BC002635.1immune responsesecreted and transmembrane 1SECTM12.29BF939675membrane proteinH.sapiens mRNA for interleukin-15--2.24Y09908.1--GREB1 proteinGREB12.24NM_014668.1--adiponectin receptor 2ADIPOR22.19NM_024551.1membrane proteinhypothetical protein DKFZp434B044DKFZP434B0442.19AL136861.1extracellular matrixgastrinGAS2.19NM_000805.2signal transductionalkaline phosphatase, liver/bone/kidneyALPL2.14X14174.1metabolismchromosome 1 open reading frame 29C1orf292.14NM_006820.1--Fas apoptotic inhibitory moleculeFAIM2.14NM_018147.1--KIAA0089 proteinKIAA00892.14AA135522metabolismPOU domain, class 5, transcription factor 1POU5F12.14NM_002701.1transcription factorserum amyloid A2SAA22.14M23699.1immune responseSEC14-like 1 (S. cerevisiae)SEC14L12.14AV748469transportsolute carrier family 26 (sulfate transporter), member 2SLC26A22.14AI025519transportCDC14 cell division cycle 14 homolog B (S. cerevisiae)CDC14B2.09AU145941metabolismhypothetical protein FLJ11795FLJ117952.09NM_024669.1--likely ortholog of mouse tumor necrosis-alpha-induced adipose-related proteinFLJ231532.09NM_024636.1transportKIAA0960 proteinKIAA09602.09BF447246--oxysterol binding protein-like 11OSBPL112.09NM_022776.1transportprotein tyrosine phosphatase, receptor type, RPTPRR2.09NM_002849.1signal transductionfibrinogen, A alpha polypeptideFGA2.04NM_021871.1cell adhesioninterleukin 6 signal transducer (gp130, oncostatin M receptor)IL6ST2.04AB015706.1signal transductionKIAA0367 proteinKIAA03672.04AL138349--KIAA0711 gene productKIAA07112.04NM_014867.1protein bindingADP-ribosyltransferase 3ART32.00U47054.1metabolismcut-like 2 (Drosophila)CUTL22.00AB006631.1transcription factordual specificity phosphatase 1DUSP12.00AA530892metabolismeukaryotic translation initiation factor 2, subunit 3 gamma, 52kDaEIF2S32.00NM_001415.1translationinterleukin 20 receptor, alphaIL20RA2.00NM_014432.1signal transductionPRO2000 proteinPRO20002.00NM_014109.1DNA bindingsolute carrier family 7, member 2SLC7A22.00NM_003046.1transportSPARC-like 1 (mast9, hevin)SPARCL12.00NM_004684.1--toll-like receptor 2TLR22.00NM_003264.1immune responsecoagulation factor XIII, A1 polypeptideF13A1−2.00NM_000129.2metabolismprotein kinase (cAMP-dependent, catalytic) inhibitor alphaPKIA−2.00NM_006823.1metabolismglutaminyl-peptide cyclotransferase (glutaminyl cyclase)QPCT−2.00NM_012413.2metabolismTGF2_HUMAN Transforming growth factor beta 2 precursor (TGF-beta 2)--−2.04BF061658--cadherin 5, type 2, VE-cadherin (vascular epithelium)CDH5−2.04NM_001795.1cell adhesioncellular retinoic acid binding protein 2CRABP2−2.04NM_001878.2signal transductiondrebrin 1DBN1−2.04NM_004395.1structural proteindimethylarginine dimethylaminohydrolase 2DDAH2−2.04AJ012008metabolismearly growth response 1EGR1−2.04NM_001964.1transcription factorhypothetical protein FLJ11082FLJ11082−2.04NM_018317.1--matrix metalloproteinase 1 (interstitial collagenase)MMP1−2.04NM_002421.2metabolismmatrix metalloproteinase 3 (stromelysin 1, progelatinase)MMP3−2.04NM_002422.2metabolismmatrix metalloproteinase 9MMP9−2.04NM_004994.1metabolismreticulon 3RTN3−2.04NM_023941.1membrane proteinstanniocalcin 1STC1−2.04U46768.1signal transductionThy-1 cell surface antigenTHY1−2.04AL558479membrane proteintumor necrosis factor receptor superfamily, member 21TNFRSF21−2.04NM_016629.1signal transductionbasic helix-loop-helix domain containing, class B, 3BHLHB3−2.09BE857425transcription factorchromosome 21 open reading frame 7C21orf7−2.09NM_020152.1--glycoprotein A repetitions predominantGARP−2.09NM_005512.1--regulator of G-protein signalling 3RGS3−2.09NM_021106.1signal transductiontrefoil factor 1TFF1−2.09NM_003225.1growth factorATP-binding cassette, sub-family A (ABC1), member 8ABCA8−2.14NM_007168.1transporthypothetical gene BC008967BC008967−2.14BE299456--solute carrier family 14 (urea transporter), member 1SLC14A1−2.14NM_015865.1transporta disintegrin and metalloproteinase domain 12 (meltrin alpha)ADAM12−2.19NM_003474.2metabolismaquaporin 3AQP3−2.19AB001325transportcarcinoembryonic antigen-related cell adhesion molecule 6CEACAM6−2.19BC005008.1signal transductionchloride channel, calcium activated, family member 4CLCA4−2.19NM_012128.2transportchloride intracellular channel 2CLIC2−2.19AI768628transportDVS27-related proteinDVS27−2.19AB024518.1--hypothetical protein FLJ31737FLJ31737−2.19N91149--fascin homolog 1, actin-bundling proteinFSCN1−2.19NM_003088.1structural proteinsynuclein, alpha interacting protein (synphilin)SNCAIP−2.19NM_005460.1protein bindingembryonal Fyn-associated substrateEFS−2.24NM_005864.1cell adhesionintegral membrane protein 2CITM2C−2.24NM_030926.1--keratin 23 (histone deacetylase inducible)KRT23−2.24NM_015515.1--matrix metalloproteinase 27MMP27−2.24NM_022122.1metabolismpre-B-cell leukemia transcription factor 1PBX1−2.24BF967998transcriptionsuppression of tumorigenicityST7−2.24NM_013437.1--Homo sapiens mRNA, chromosome 1 specific transcript KIAA0509.--−2.29AB007978.1--apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3BAPOBEC3B−2.29NM_004900.1metabolismARF-GAP, RHO-GAP, ankyrin repeat and plekstrin homology domains-containing protein 3ARAP3−2.29NM_022481.1signal transductioncarboxypeptidase ZCPZ−2.29BC006393.1metabolismmelanoma antigen, family D, 4MAGED4−2.29NM_030801.1--matrilin 4MATN4−2.29NM_003833.2extracellular matrixregulator of G-protein signalling 4RGS4−2.29AL514445signal transductionchromosome 6 open reading frame 59C6orf59−2.34NM_020133.1--aldo-keto reductase family 1, member B10 (aldose reductase)AKR1B10−2.40NM_020299.1metabolismangiopoietin 2ANGPT2−2.40AF187858.1signal transductiondapper homolog 1, antagonist of beta-catenin (xenopus)DACT1−2.40NM_016651.2nuclearG protein-coupled receptor 17GPR17−2.40NM_005291.1signal transductionglutathione peroxidase 2 (gastrointestinal)GPX2−2.40NM_002083.1metabolismmicrofibrillar-associated protein 2MFAP2−2.40NM_017459.1extracellular matrixtransforming growth factor, beta 3TGFB3−2.40J03241.1growth factorWNT1 inducible signaling pathway protein 2WISP2−2.40NM_003881.1signal transductionhepatocyte growth factor (hepapoietin A; scatter factor)HGF−2.45M77227.1growth factorKIAA1277 proteinKIAA1277−2.45AA127623--matrix metalloproteinase 14 (membrane-inserted)MMP14−2.45AU149305metabolismRas family member RisRIS−2.45NM_016563.1signal transductionthymosin, beta, identified in neuroblastoma cellsTMSNB−2.45NM_021992.1structural proteinlatexin proteinLXN−2.51NM_020169.1--serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 2SERPINB2−2.51NM_002575.1cell growthcarbonic anhydrase IICA2−2.57M36532.1metabolismdeleted in malignant brain tumors 1DMBT1−2.57NM_004406.1cell growthfibronectin leucine rich transmembrane protein 2FLRT2−2.57NM_013231.1cell adhesionorosomucoid 1ORM1−2.57NM_000608.1transportstathmin-like 2STMN2−2.57BF967657signal transductionsynaptojanin 2SYNJ2−2.57AF318616.1metabolismcarcinoembryonic antigen-related cell adhesion molecule 5CEACAM5−2.63NM_004363.1membrane proteinectodermal-neural cortex (with BTB-like domain)ENC1−2.63NM_003633.1protein bindingmucin 4, tracheobronchialMUC4−2.63AJ242547.1signal transductionprotocadherin 16 dachsous-like (Drosophila)PCDH16−2.63BF222893cell adhesioninterleukin 24IL24−2.69NM_006850.1signal transductiontransforming growth factor, beta 2TGFB2−2.69NM_003238.1growth factorintegrin, beta 3 (platelet glycoprotein IIIa, antigen CD61)ITGB3−2.75M35999.1cell adhesionplasminogen activator, urokinasePLAU−2.75NM_002658.1metabolismchromosome 20 open reading frame 42C20orf42−2.82NM_017671.1--four jointed box 1 (Drosophila)FJX1−2.82NM_014344.1--ephrin-B2EFNB2−2.88BF001670cell growthparathyroid hormone-like hormonePTHLH−2.88BC005961.1signal transductiontribbles homolog 2TRB2−2.88NM_021643.1metabolismtwist homolog 1TWIST1−2.88X99268.1DNA bindinggap junction protein, alpha 4, 37kDa (connexin 37)GJA4-2.95NM_002060.1transportintegrin, beta 6ITGB6−2.95NM_000888.3cell adhesionbradykinin receptor B1BDKRB1−3.02NM_000710.1signal transductionsolute carrier family 21 (organic anion transporter), member 11SLC21A11−3.02NM_013272.2transportmyristoylated alanine-rich protein kinase C substrateMARCKS−3.09M68956.1membrane proteinangiopoietin-like 2ANGPTL2−3.16NM_012098.1signal transductiontumor necrosis factor receptor superfamily, member 11b (osteoprotegerin) TNFRSF11B−3.16NM_002546.1signal transductionacid phosphatase, prostateACPP−3.24NM_001099.2metabolismhomeo box A11HOXA11−3.24NM_005523.3transcription factorhypothetical protein FLJ38993FLJ38993−3.31AF070524.1signal transductionmatrix metalloproteinase 11 (stromelysin 3)MMP11−3.31AI761713metabolismpleckstrin 2PLEK2−3.31NM_016445.1signal transductionSRY (sex determining region Y)-box 9SOX9−3.31NM_000346.1DNA bindinglymphocyte-specific protein tyrosine kinaseLCK−3.39NM_005356.1signal transductionBDG-29 protenBDG29−3.47AL117532.1DNA bindingdeiodinase, iodothyronine, type IIDIO2−3.47U53506.1metabolismSRY (sex determining region Y)-box 4SOX4−3.47AI989477transcription factorcysteine knot superfamily 1, BMP antagonist 1CKTSF1B1−3.63AF154054.1--chromogranin A (parathyroid secretory protein 1)CHGA−3.72NM_001275.2transportcystic fibrosis transmembrane conductance regulator, ATP-binding cassetteCFTR−4.07NM_000492.2transportRas-induced senescence 1RIS1−4.07BF062629--hypothetical protein FLJ10640FLJ10640−4.17NM_024703.1metabolismribosomal protein S20RPS20−4.27AF113008.1protein biosynthesisSRY (sex determining region Y)-box 11SOX11−4.68AB028641.1transcription factorplatelet-derived growth factor beta polypeptidePDGFB−5.75NM_002608.1growth factorribosomal protein L27aRPL27A−5.75BE737027protein biosynthesisGene transcripts regulated (≥2-fold) by 17β-E~2~+P in late proliferative phase explants when compared to the vehicle-treated controls. Data are presented as fold changes.Table 3Genes affected by progesterone alone in explants of late proliferative phase endometrium.GeneGene Symbolfold changeAccession \#Functioncytochrome P450, family 26, subfamily A, polypeptide 1CYP26A128.84NM_000783.1metabolismcalpain 6CAPN619.50NM_014289.2metabolism**hemoglobin, alpha 2**--**12.88V00489**--heart and neural crest derivatives expressed 2HAND210.96NM_021973.1transcription factorsecretoglobin, family 1D, member 2SCGB1D29.55NM_006551.2extracellular matrixcarbohydrate (N-acetylglucosamine 6-O) sulfotransferase 7CHST77.59NM_019886.1metabolismglycine-N-acyltransferaseGLYAT7.08AW024233metabolismFK506 binding protein 5FKBP56.31NM_004117.1metabolismPDZ domain containing 3PDZK36.17AF338650.1signal transductionneuronal pentraxin IINPTX26.03U26662.1cell adhesionchemokine (C-X-C motif) ligand 11CXCL115.50AF030514.1signal transductionsolute carrier family 7, member 8SLC7A85.25NM_012244.1transporta disintegrin-like and metalloprotease with thrombospondin type 1 motif, 8ADAMTS85.01NM_007037.1metabolismdickkopf homolog 1 (Xenopus laevis)DKK15.01NM_012242.1growth factorkeratin 6AKRT6A4.90J00269.1structural proteinalkaline phosphatase, placental (Regan isozyme)ALPP4.79NM_001632.2metabolismapolipoprotein DAPOD4.68NM_001647.1transportG protein-coupled receptor 105GPR1054.68NM_014879.1signal transductionprostaglandin-endoperoxide synthase 1PTGS14.68NM_000962.1metabolism**TU3A proteinTU3A4.68AL050264.1**--hemoglobin, alpha 1HBA14.57AF105974.1transportmitogen-activated protein kinase kinase 6MAP2K64.27NM_002758.1signal transductionkeratin 6BKRT6B4.07L42612.1structural protein**claudin 5CLDN53.98NM_003277.1structural protein**regulator of G-protein signalling 2, 24kDaRGS23.98NM_002923.1signal transductionRGC32 proteinRGC323.89NM_014059.1cell growthintegrin, beta-like 1ITGBL13.80NM_004791.1cell adhesionsolute carrier family 15, member 2SLC15A23.72BF223679transportdelta sleep inducing peptide, immunoreactorDSIPI3.55AL110191.1transcription factor**myosin heavy chain Myr 8MYR83.55AI522028metabolism**potassium inwardly-rectifying channel, subfamily J, member 8KCNJ83.31NM_004982.1transportpaired basic amino acid cleaving system 4PACE43.31NM_002570.1signal transductioncannabinoid receptor 1 (brain)CNR13.24U73304signal transductionhypothetical protein FLJ11539FLJ115393.24NM_024748.1--protein kinase, X-linkedPRKX3.24NM_005044.1metabolismlatent transforming growth factor beta binding protein 1LTBP13.16NM_000627.1protein bindingKIAA0960 proteinKIAA09603.09BF447246--nuclear factor I/BNFIB3.02AI186739transcription factorsushi-repeat-containing protein, X-linkedSRPX3.02NM_006307.1cell adhesioncytochrome P450, family 4, subfamily B, polypeptide 1CYP4B12.95J02871.1metabolisminsulin receptor substrate 2IRS22.95BF700086signal transductionpotassium voltage-gated channel, subfamily G, member 1KCNG12.95AI332979transportArg/Abl-interacting protein ArgBP2ARGBP22.88NM_021069.1structural proteinhemoglobin, betaHBB2.88M25079.1transport**Homo sapiens mutant beta-globin (HBB) gene, complete cds.--2.82AF059180--RAR-related orphan receptor BRORB2.82NM_006914.1transcription factor**S100 calcium binding protein A2S100A22.75NM_005978.2transportserum amyloid A2SAA22.75NM_030754.1immune response**absent in melanoma 1-likeAIM1L2.69NM_017977.1--RIM binding protein 2KIAA03182.69AB002316.1transport**thrombomodulinTHBD2.69NM_000361.1signal transductioncytokine receptor-like factor 1CRLF12.63NM_004750.1signal transduction**v-maf musculoaponeurotic fibrosarcoma oncogene homolog (avian)MAF2.51NM_005360.2transcription factor**monoamine oxidase BMAOB2.51NM_000898.1transportsecretoglobin, family 1D, member 1SCGB1D12.51NM_006552.1extracellular matrix**interleukin 15IL152.45NM_000585.1signal transduction**hypothetical protein FLJ20701FLJ207012.45NM_017933.1--secretoglobin, family 2A, member 1SCGB2A12.45NM_002407.1hormone bindingdipeptidylpeptidase 4DPP42.40M80536.1metabolism**immunoglobulin kappa constantIGKC2.40BC005332.1immune responseimmunoglobulin heavy constant gamma 3 (G3 m marker)IGHG32.34M87789.1immune response**iroquois homeobox protein 4IRX42.34NM_016358.1transcription factor**killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 1KIR2DS12.34NM_014512.1immune response**metallothionein 1KMT1K2.34R06655transportamylase, alpha 1A; salivaryAMY1A2.29NM_004038.1metabolismcreatine kinase, brainCKB2.29NM_001823.1metabolismcut-like 2 (Drosophila)CUTL22.29AB006631.1transcription factorfatty-acid-Coenzyme A ligase, long-chain 2FACL22.29NM_001995.1metabolismPRO2000 proteinPRO20002.29NM_014109.1DNA bindingserine (or cysteine) proteinase inhibitor, clade E , member 1SERPINE12.29NM_000602.1metabolismadiponectin receptor 2ADIPOR22.24NM_024551.1membrane proteinalkaline phosphatase, liver/bone/kidneyALPL2.24X14174.1metabolism**N-acylsphingosine amidohydrolase (acid ceramidase)-likeASAHL2.24AK024677.1metabolism**hypothetical protein FLJ20366FLJ203662.24NM_017786.1--Norrie disease (pseudoglioma)NDP2.24NM_000266.1signal transduction**zinc finger, BED domain containing 2ZBED22.24NM_024508.1DNA binding**zinc finger protein 145ZNF1452.24NM_006006.1protein bindingFas apoptotic inhibitory moleculeFAIM2.19NM_018147.1--insulin-like growth factor binding protein 1IGFBP12.19NM_000596.1signal transductioninterleukin 20 receptor, alphaIL20RA2.19NM_014432.1signal transduction**mesothelinMSLN2.19NM_005823.2--**secreted and transmembrane 1SECTM12.19BF939675membrane proteinCDC14 cell division cycle 14 homolog BCDC14B2.14AU145941metabolism**cathepsin ECTSE2.14NM_001910.1metabolismLIM and cysteine-rich domains 1LMCD12.14NM_014583.1--**monoamine oxidase AMAOA2.14NM_000240.1transporttoll-like receptor 2TLR22.14NM_003264.1signal transduction**Homo sapiens mRNA; cDNA DKFZp586B0220--2.09AL049435.1--**hypothetical protein DKFZp434B044DKFZP434B0442.09AL136861.1extracellular matrix**glutamyl aminopeptidaseENPEP2.09L12468.1metabolismepithelial V-like antigen 1EVA12.09NM_005797.1cell adhesionfibulin 2FBLN22.09NM_001998.1extracellular matrix**KIAA0924 proteinKIAA09242.09NM_014897.1nuclear**KIAA1609 proteinKIAA16092.09AA195017--neuroligin 4NLGN42.09AI338338cell adhesion**peroxisome proliferative activated receptor, gamma, coactivator 1PPARGC12.09NM_013261.1DNA bindingsolute carrier family 26, member 2SLC26A22.09AI025519transport**CDC42 effector protein 3CDC42EP32.04AI754416--**GREB1 proteinGREB12.04NM_014668.1--interleukin 1 receptor-like 1IL1RL12.04NM_003856.1signal transduction**leucine-rich repeat-containing 1LRRC12.04NM_018214.1--protein kinase, AMP-activated, gamma 2 non-catalytic subunitPRKAG22.04NM_016203.1metabolism**SPARC-like 1 (mast9, hevin)SPARCL12.04NM_004684.1--**chromosome 18 open reading frame 1C18orf12.00NM_004338.1membrane proteincholine phosphotransferase 1CHPT12.00AF195624.1metabolismendothelial differentiation, lysophosphatidic acid G-protein-coupled receptor, 7EDG72.00NM_012152.1signal transduction**retinol binding protein 4, plasmaRBP42.00NM_006744.2transportcarcinoembryonic antigen-related cell adhesion molecule 5CEACAM5−2.00NM_004363.1membrane protein**chromosome condensation 1CHC12.00NM_001269.1cell growthcytochrome P450, family 27, subfamily B, polypeptide 1CYP27B12.00NM_000785.1metabolismDVS27-related proteinDVS272.00AB024518.1--**four jointed box 1 (Drosophila)FJX1−2.00NM_014344.1--interleukin 24IL24−2.00NM_006850.1cell growthmatrix metalloproteinase 11 (stromelysin 3)MMP11−2.00AI761713metabolismsynaptojanin 2SYNJ2−2.00AF318616.1metabolismaldo-keto reductase family 1, member B10 (aldose reductase)AKR1B10−2.04NM_020299.1metabolism**neuromedin BNMB2.04NM_021077.1signal transduction**pleckstrin 2PLEK2−2.04NM_016445.1structural protein**transmembrane protease, serine 3TMPRSS32.04NM_024022.1metabolism**twist homolog 1TWIST1−2.04X99268.1DNA bindinghypothetical protein FLJ38993FLJ38993−2.09AF070524.1signal transduction**somatostatinSST2.09NM_001048.1signal transduction**chromosome 21 open reading frame 7C21orf7−2.14NM_020152.1--**carboxypeptidase MCPM2.14NM_001874.1metabolism**glutathione peroxidase 2 (gastrointestinal)GPX2−2.14NM_002083.1metabolismorosomucoid 1ORM1−2.14NM_000607.1transportserine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 2SERPINB2−2.14NM_002575.1cell growthsolute carrier family 14 (urea transporter), member 1SLC14A1−2.14NM_015865.1transportSRY (sex determining region Y)-box 4SOX4−2.14AI989477transcription factortribbles homolog 2TRB2−2.14NM_021643.1metabolismchromosome 20 open reading frame 42C20orf42−2.19NM_017671.1--dapper homolog 1, antagonist of beta-catenin (xenopus)DACT1−2.19NM_016651.2nuclear**ectodermal-neural cortexENC12.24AF010314.1protein binding**keratin 23KRT23−2.24NM_015515.1--deiodinase, iodothyronine, type IIDIO2−2.29U53506.1metabolismplasminogen activator, urokinasePLAU−2.29NM_002658.1metabolism**NY-REN-7 antigenNY-REN-72.34AL117630.1--**stanniocalcin 1STC1−2.40U46768.1signal transductioncarbonic anhydrase IICA2−2.45M36532.1metabolismG protein-coupled receptor 17GPR17−2.45NM_005291.1signal transduction**high mobility group AT-hook 1HMGA12.45AF176039.1transcription**Ras-induced senescence 1RIS1−2.45BF062629--trefoil factor 1TFF1−2.45NM_003225.1growth factorWNT1 inducible signaling pathway protein 2WISP2−2.45NM_003881.1signal transductionaquaporin 3AQP3−2.51AB001325transportSRY (sex determining region Y)-box 9SOX9−2.51NM_000346.1transcriptionbradykinin receptor B1BDKRB1−2.57NM_000710.1signal transductionephrin-B2EFNB2−2.57U16797.1signal transductiongap junction protein, alpha 4, 37kDa (connexin 37)GJA4−2.57NM_002060.1transportmyristoylated alanine-rich protein kinase C substrateMARCKS−2.88AW163148structural proteintumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)TNFRSF11B−2.88NM_002546.1signal transduction**small proline-rich protein 2BSPRR2B2.95NM_006945.1structural protein**chromogranin A (parathyroid secretory protein 1)CHGA−3.02NM_001275.2transport**Homo sapiens non-functional folate binding protein (HSAF000381), mRNA--3.16NM_013307.1--**acid phosphatase, prostateACPP−3.31NM_001099.2metabolismintegrin, beta 3ITGB3−3.47M35999.1cell adhesionplatelet-derived growth factor beta polypeptidePDGFB−3.47NM_002608.1growth factorSRY (sex determining region Y)-box 11SOX11−3.72AB028641.1transcription factorcysteine knot superfamily 1, BMP antagonist 1CKTSF1B1−3.89AF154054.1--ribosomal protein S20RPS20−6.17AF113008.1protein biosynthesisribosomal protein L27aRPL27A−7.59BE737027protein biosynthesisGene transcripts regulated (≥2-fold) by progesterone alone in late proliferative phase explants when compared to the vehicle-treated controls. Data are presented as fold changes. The genes in bold were not found to be modulated by 17β-oestradiol and progesterone (17β-E~2~+P).

The response of menstrual phase endometrium to 17β-E~2~+P was less pronounced than that of late proliferative phase endometrium. Treatment of menstrual phase endometrial tissue with 17β-E~2~+P up-regulated (≥2-fold) the expression of only 38 gene transcripts and down-regulated (≥2-fold) the expression of 79 gene transcripts when compared to the control sample (vehicle) (Table [4](#Tab4){ref-type="table"}). Table 4Genes affected by 17β-oestradiol and progesterone (17β−E~2~+P) in explants of menstrual phase endometrium.GeneGene Symbolfold changeAccession \#functionsecretoglobin, family 1D, member 2SCGB1D260.26NM_006551.2extracellular matrixalkaline phosphatase, placental (Regan isozyme)ALPP10.00NM_001632.2metabolismhypothetical protein FLJ10847FLJ108477.08NM_018242.1transportsecretoglobin, family 2A, member 1SCGB2A16.92NM_002407.1hormone bindingsecretoglobin, family 2A, member 2SCGB2A26.03NM_002411.1hormone bindingtrefoil factor 1TFF15.13NM_003225.1growth factorcytochrome P450, family 26, subfamily A, polypeptide 1CYP26A14.68NM_000783.1transportcarbohydrate (N-acetylglucosamine 6-O) sulfotransferase 7CHST74.57NM_019886.1metabolismhypothetical protein FLJ10640FLJ106403.47NM_024703.1metabolismhydroxysteroid (17-beta) dehydrogenase 2HSD17B23.39NM_002153.1metabolismpaired box gene 5 (B-cell lineage specific activator protein)PAX53.31NM_016734.1transcription factorapolipoprotein DAPOD3.09NM_001647.1transportsolute carrier family 7 (cationic amino acid transporter, y+ system), member 8SLC7A82.75NM_012244.1transportDNA segment on chromosome 4 (unique) 234 expressed sequenceD4S234E2.69NM_014392.1nuclearGREB1 proteinGREB12.69NM_014668.1--anthrax toxin receptor 1ANTXR12.63NM_018153.1membrane proteinhistone 1, H2bdHIST1H2BD2.63AL353759DNA bindingprostaglandin-endoperoxide synthase 2PTGS22.63NM_000963.1metabolismheat shock 70kDa protein 6 (HSP70B')HSPA62.57NM_002155.1metabolismcyclin A1CCNA12.45NM_003914.1cell growthasparaginase like 1ASRGL12.40NM_025080.1metabolismapolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3BAPOBEC3B2.34NM_004900.1metabolismhypothetical protein FLJ20152FLJ201522.34AI816291--histone 1, H2bhHIST1H2BH2.34NM_003524.1DNA bindingHomo sapiens mRNA; cDNA DKFZp564G112--2.24AA053967--crystallin, alpha BCRYAB2.19AF007162.1structural proteincolony stimulating factor 3 (granulocyte)CSF32.19NM_000759.1signal transductionhistone 1, H1cHIST1H1C2.19BC002649.1DNA bindinginsulin-like growth factor binding protein 1IGFBP12.19NM_000596.1signal transductionserine (or cysteine) proteinase inhibitor, clade A, member 3SERPINA32.19NM_001085.2immune responsapolipoprotein MAPOM2.14NM_019101.1transportpiggyBac transposable element derived 5PGBD52.14NM_024554.1--trefoil factor 3 (intestinal)TFF32.14NM_003226.1immune responshistone 1, H2biHIST1H2BI2.04NM_003525.1DNA bindingH2B histone family, member SH2BFS2.00NM_017445.1DNA bindingputative chemokine receptorHM742.00NM_006018.1signal transductionmetallothionein 1XMT1X2.00NM_002450.1transportTUWD12TUWD122.00NM_003774.2--hyaluronan binding protein 2HABP2−2.00NM_004132.1metabolisminterleukin 2 receptor, betaIL2RB−2.00NM_000878.1immune responsmyosin, light polypeptide kinaseMYLK−2.00NM_005965.1signal transductionSAM and SH3 domain containing 1SASH1−2.00AK025495.1cell growthtransglutaminase 2TGM2−2.00BC003551.1metabolismadipose specific 2APM2−2.04NM_006829.1--Microfibril-associated glycoprotein-2MAGP2−2.04AW665892extracellular matrix3-phosphoinositide dependent protein kinase-1PDPK1−2.04NM_002613.1signal transductionpolymerase (RNA) II (DNA directed) polypeptide J, 13.3kDaPOLR2J−2.04AI738591DNA bindingpreferentially expressed antigen in melanomaPRAME−2.04NM_006115.1--transmembrane protein 5TMEM5−2.04BF224146membrane proteinleucine-rich repeat-containing 5LRRC5−2.09NM_018103.1--parathyroid hormone receptor 2PTHR2−2.09NM_005048.1signal transductionretinoblastoma binding protein 6RBBP6−2.09NM_006910.1cell growthcadherin 6, type 2, K-cadherin (fetal kidney)CDH6−2.14AU151483cell adhesionv-myc myelocytomatosis viral related oncogene, neuroblastoma derived (avian)MYCN−2.14BC002712.1transcription factorSRY (sex determining region Y)-box 4SOX4−2.14AI989477transcriptionzinc finger, BED domain containing 2ZBED2−2.14NM_024508.1DNA bindingATP-binding cassette, sub-family C (CFTR/MRP), member 3ABCC3−2.19AF009670.1transporthypothetical protein LOC339290LOC339290−2.19H49382--hypothetical protein MGC29643MGC29643−2.19AL567376--transcription factor 4TCF4−2.19AU118026transcription factornudix (nucleoside diphosphate linked moiety X)-type motif 6NUDT6−2.24NM_007083.1growth factorribosomal protein S6 kinase, 90kDa, polypeptide 5RPS6KA5−2.24AF074393.1metabolismheme oxygenase (decycling) 1HMOX1−2.29NM_002133.1metabolismkiller cell lectin-like receptor subfamily B, member 1KLRB1−2.29NM_002258.1signal transductionPTPRF interacting protein, binding protein 2 (liprin beta 2)PPFIBP2−2.29AI692180DNA bindingubiquitin DUBD−2.29NM_006398.1--laminin, alpha 3LAMA3−2.34NM_000227.1structural proteinribonucleotide reductase M2 polypeptideRRM2−2.34BE966236metabolismRho guanine nucleotide exchange factor (GEF) 17ARHGEF17−2.40NM_014786.1--N-myristoyltransferase 1NMT1−2.40AI570834metabolismHomo sapiens cDNA: FLJ22812 fis, clone KAIA2955--−2.45AK026465.1--solute carrier family 16 (monocarboxylic acid transporters), member 6SLC16A6−2.45NM_004694.1transportspondin 1, (f-spondin) extracellular matrix proteinSPON1−2.45AI885290extracellular matrixATP synthase, H+ transporting, mitochondrial F0 complex, subunit s (factor B)ATP5S−2.51NM_015684.1--chemokine (C-C motif) ligand 5CCL5−2.51M21121signal transductionCD96 antigenCD96−2.51NM_005816.1cell adhesiongrowth associated protein 43GAP43−2.51NM_002045.1cell growthhistone H2A.F/Z variantH2AV−2.51BF343852DNA bindingtumor necrosis factor receptor superfamily, member 4TNFRSF4−2.51AJ277151immune responschemokine (C motif) ligand 1XCL1−2.57U23772.1signal transductionHomo sapiens transcribed sequences--−2.63BE045982--C-terminal binding protein 1CTBP1−2.63AA053830metabolismfibroblast growth factor 9 (glia-activating factor)FGF9−2.63NM_002010.1growth factorlatexin proteinLXN−2.63NM_020169.1--protocadherin gamma subfamily C, 3PCDHGC3−2.63AB002325.1transportcathepsin W (lymphopain)CTSW−2.75NM_001335.1metabolismdual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2DYRK2−2.75NM_006482.1metabolismintegrin, beta 6ITGB6−2.75NM_000888.3signal transductionhypothetical protein LOC284266LOC284266−2.75AK025833.1--platelet-derived growth factor alpha polypeptidePDGFA−2.75X03795.1growth factorchromosome 14 open reading frame 117C14orf117−2.82NM_018678.1--chromosome 20 open reading frame 42C20orf42−2.82NM_017671.1--insulin-like growth factor binding protein 3IGFBP3−2.82BF340228signal transductionchloride intracellular channel 3CLIC3−2.88NM_004669.1signal transductionhypothetical protein FLJ11082FLJ11082−2.88NM_018317.1--glutathione S-transferase theta 1GSTT1−2.88NM_000853.1metabolismB/K proteinLOC51760−2.95NM_016524.1transportretinoic acid receptor responder (tazarotene induced) 1RARRES1−2.95AI669229cell growthHomo sapiens, clone IMAGE:4866926, mRNA--−3.09AA631242--chemokine (C-X-C motif) ligand 14CXCL14−3.09NM_004887.1signal transductionchemokine (C motif) ligand 2XCL2−3.09NM_003175.1signal transductioncytidine deaminaseCDA−3.16NM_001785.1metabolismerythrocyte membrane protein band 4.1 like 4AEPB41L4A−3.39NM_022140.1structural proteinzinc finger protein 426ZNF426−3.39NM_024106.1transcription factorregulator of G-protein signalling 5RGS5−3.63AI183997signal transductionKIAA0924 proteinKIAA0924−3.72NM_014897.1nuclearserine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 5SERPINB5−4.07NM_002639.1cell adhesionkiller cell lectin-like receptor subfamily C, member 3KLRC3−4.17NM_002260.2immune responsecalcium channel, voltage-dependent, alpha 1G subunitCACNA1G−4.27NM_018896.1transportprotein phosphatase 1, regulatory (inhibitor) subunit 16BPPP1R16B−4.47AB020630signal transductionHomo sapiens mRNA; cDNA DKFZp564N1116--−4.68BF344237--integral membrane protein 2AITM2A−4.79NM_004867.1membrane proteinphosphoribosylformylglycinamidine synthase (FGAR amidotransferase)PFAS−4.90AL044326metabolismmajor histocompatibility complex, class II, DR beta 3HLA-DRB3−5.13BC005312.1immune responseimmunoglobulin lambda joining 3IGLJ3−5.62X57812.1--fibroblast growth factor 18FGF18−6.92BC006245.1growth factorcystic fibrosis transmembrane conductance regulator, ATP-binding cassetteCFTR−8.32NM_000492.2transportGene transcripts regulated (≥2-fold) by 17β-E~2~+P in menstrual phase explants when compared to vehicle-treated controls. Data are presented as fold changes.

Almost all genes modulated by 17β-E~2~+P in late proliferative phase endometrium were specific for that phase of the cycle. Of the 110 up-regulated (≥2- fold) gene transcripts, 100 were expressed in late proliferative phase explants and not menstrual phase explants; of these, 10 gene transcripts were documented to be up-regulated during the window of implantation (Table [5](#Tab5){ref-type="table"}). Of the 107 down-regulated (≥2-fold) gene transcripts, 102 were selective for late proliferative phase explants; of these, 7 genes were documented to be down-regulated during the implantation window (Table [5](#Tab5){ref-type="table"}). The genes regulated by 17β-E~2~+P in both menstrual and late proliferative phase explants are presented in Table [6](#Tab6){ref-type="table"}. Table 5Genes affected by 17β-E~2~+P and reported to be altered in the implantation window.GeneSymbolfold changeAccession \#Kao et al.Riesewijk et al.Carson et al.dickkopf homolog 1DKK16.03NM_012242.112.1712.6thrombomodulinTHBD3.24NM_000361.110fibrinogen-like 2FGL22.88NM_006682.15monoamine oxidase AMAOA2.88NM_000240.17.515retinol binding protein 4, plasmaRBP42.88NM_006744.26dipeptidylpeptidase 4DPP42.57M80536.115nuclear factor I/BNFIB2.57AI18673910H.sapiens mRNA for interleukin-15--2.24Y09908.13.732.2gastrinGAS2.19NM_000805.211KIAA0367 proteinKIAA03672.04AL1383494coagulation factor XIII, A1 polypeptideF13A1−2.00NM_000129.2−4.1microfibrillar-associated protein 2MFAP2−2.40NM_017459.1−transforming growth factor, beta 3TGFB3−2.40J03241.1−2.44gap junction protein, alpha 4, 37kDa (connexin 37)GJA4−2.95NM_002060.1−20myristoylated alanine-rich protein kinase C substrateMARCKS−3.09M68956.1−2.2matrix metalloproteinase 11 (stromelysin 3)MMP11−3.31AI761713−10deiodinase, iodothyronine, type IIDIO2−3.47U53506.1−2.4Gene transcripts regulated (≥2-fold) by 17β-oestradiol and progesterone (17β-E~2~+P) that have also been reported to be altered during the window of implantation (by Riesewijk et al. \[[@CR2]\], Carson et al. \[[@CR20]\] and Kao et al \[[@CR21]\]).Table 6Genes affected by 17β-E~2~+P in explants of both menstrual and late proliferative phase endometrium.GeneGene Symbolfold change Mfold change LPAccession \#Functionalkaline phosphatase, placental (Regan isozyme)ALPP10.004.79NM_001632.2metabolismapolipoprotein DAPOD3.094.90NM_001647.1transportcarbohydrate (N-acetylglucosamine 6-O) sulfotransferase 7CHST74.577.08NM_019886.1metabolismcytochrome P450, family 26, subfamily A, polypeptide 1CYP26A14.6833.11NM_000783.1transportGREB1 proteinGREB12.692.24NM_014668.1unknowninsulin-like growth factor binding protein 1IGFBP12.192.45NM_000596.1signal transductionsecretoglobin, family 1D, member 2SCGB1D260.2610.00NM_006551.2unknownsecretoglobin, family 2A, member 1SCGB2A16.922.63NM_002407.1signal transductionsolute carrier family 7 (cationic amino acid transporter, y+ system), member 8SLC7A82.754.37NM_012244.1transportchromosome 20 open reading frame 42C20orf42−2.82−2.82NM_017671.1unknowncystic fibrosis transmembrane conductance regulatorCFTR−8.32−4.07NM_000492.2transporthypothetical protein FLJ11082FLJ11082−2.88−2.04NM_018317.1unknownintegrin, beta 6ITGB62.75−2.95NM_000888.3cell adhesionlatexin proteinLXN−2.63−2.51NM_020169.1unknownGene transcripts regulated (≥2-fold) by 17∇-oestradiol and progesterone (17β-E~2~+P) in both menstrual (M) and late proliferative (LP) phase explants when compared to their respective vehicle-treated controls. Data are presented as fold changes.

**Ingenuity Pathways Analysis.** Ingenuity Pathways Analysis revealed various significant networks of interconnected focus genes after treatment with 17β-E~2~+P. In late proliferative phase endometrium, five highly significant networks were identified. Network 1 connected nodes IL1B, PLAU, MMP1, MMP3, MMP7, MMP9, SERPINE1 and EDN1; network 2 connected IL8, MMP14, FGF2, PDGFB, ITGB3, PDGFRA, PDGFRB, PTGS2 and EGR1; network 3 related TGFβ2, TGFβ3, INHBA, PTHLH, JUN, SMAD3 and SMAD7; network 4 linked IGF1, TNFSF11 and HOXA9; and network 5 coupled ICAM1, CXCL10, IL15, SOCS1, RARα and ARNT2. Network 1 is illustrated in Figure [3](#Fig3){ref-type="fig"}. Figure 3Example of a highly significant network identified in the gene expression profile of late proliferative phase endometrium treated with 17β-oestradiol and progesterone (17β-E~2~+P) as determined by the Ingenuity Pathways Analysis program. Green indicates down=regulated genes, and pink indicates up-regulated genes.

In contrast, in menstrual phase endometrium only two highly significant networks were extracted from the data. One network connected CCL5, TNFS11, INTGB3, MAPK8 and ESR1. The second network linked IFGBP3, TGFβ2, FGF2, HGF, PDGFA, MMP9, PTGS2, RARβ and EGR1. The latter network is presented in Figure [2](#Fig2){ref-type="fig"}.

Discussion {#Sec4}
==========

Previous work in our laboratory has shown that explant cultures of human endometrial tissue are biologically relevant *in vitro* models to investigate oestrogen regulation of gene expression and proliferation \[[@CR12], [@CR16]\]. With regard to progestins, it has been shown that tissue cultures of human endometrium are also responsive, as evidenced by the suppressive effects on the production and activation of MMPs \[[@CR12]--[@CR14]\]. The present study was designed to gain more insight into the responses of human endometrium to P with regard to gene expression and the influence of 17β-E~2~. The results show that in explant cultures of human endometrium, the expression of genes that have been implicated in the process of embryo implantation can be modulated by 17β-E~2~ and P. Figure 4Relative expression levels of gene transcripts for DKK1, THBD, MAOA, GAS, CDA and SPARCL1 in early secretory (*n*=7) and mid-secretory (*n*=8) endometrium, which represent endometrial tissues exposed to low (pre-implantation window) and high (implantation window) progesterone concentrations, respectively (\**p*\<0.05).

The number of gene transcripts regulated by P in late proliferative phase explants was almost twice the number regulated in menstrual phase explants, indicating that oestrogen priming sensitizes the endometrium for P regulation, most likely by induction of P receptor gene expression \[[@CR16]\]. In addition, most of these genes were specifically modulated in the late proliferative phase endometrium. Of these genes (*n*=100), at least 17 were previously described to be regulated in the implantation window (Table [5](#Tab5){ref-type="table"}) \[[@CR2], [@CR20], [@CR21]\]. Three examples of such genes areDKK1, MAOA and SPARCL1. Regulation of expression by 17β-E~2~+P and P alone was confirmed with real-time PCR in both explant cultures and endometrium biopsy specimens collected during the implantation window and ES phase. These findings demonstrate that the expression of genes associated with the implantation window can be modulated in explant cultures of human endometrium and that for most of these genes, prolonged *in vivo* exposure to 17β-E~2~ is required for adequate P regulation. These findings also support the hypothesis that variations in the duration of 17β-E~2~ priming can affect the response of the endometrium to P and therefore the subsequent implantation process \[[@CR11], [@CR22]\].

The number of implantation-associated gene transcripts, however, was rather low. This could be because the culturing of explants alters the physiology of the tissue and therefore its steroid responsiveness or because, as shown for prolactin and IGFBP1, in some cases prolonged exposure to P is required for genes to respond \[[@CR23]\]; the latter finding is supported by a report from Kao and coworkers showing that many genes up-regulated in the implantation window are not yet regulated in ES endometrium, at which time the endometrium has been exposed to P for only a short time \[[@CR21]\]. Explant cultures are therefore appropriate models to study immediate responses of human endometrium to oestrogens and progestins *ex vivo* but do not allow investigation of the entire spectrum of implantation-associated genes.

The low number of implantation-related genes identified may also be a result of the relatively low number of samples used for the initial microarray hybridizations, which increases the likelihood of missing relevant genes and the chance of generating false positives. At the time the microarray experiments were performed, we opted to carry out a limited number of array hybridizations so that we could apply rigorous statistical procedures and perform extensive validation of selected genes for both the array samples and samples from additional independent experiments. Rockett and Hellmann asked the questions: how many genes should we pick for validation, and which genes should we pick? The authors argue that genes can be selected to ensure successful confirmation, *i.e.* by selecting genes that have changed more than 4-fold \[[@CR24]\] or by selecting genes that have been reported to be changed in similar models or conditions \[[@CR25]\].We selected six genes primarily based on the fact that their expression is altered during the implantation window. In addition, we selected two genes that have not yet been reported in the endometrium. With the exception of DKK1 (more than 5-fold induction), the expression of the selected genes changed less than 3- fold. We could confirm steroid regulation for four of eight genes in independent experiments, which justifies our approach.

Rockett and Hellmann also questioned the additive value of corroborating the findings of microarray experiments with alternative means of quantitating the mRNA abundance of a limited number of genes of the array \[[@CR25]\]. The vast majority of studies published state that the DNA array data can be corroborated, indicating that the array data are reliable as long as the experimental design and statistical analysis is sound. Even in high-impact journals, studies that have not been validated are being published; Goodman illustrated this by showing that our of 28 microarray papers in Science, Cell and Nature published in 2002, only 11 reported corroborative studies \[[@CR26]\]. It is evident that clear standards, such as the guideline Minimal Information about a Microarray Experiment (MIAME), in the confirmatory studies area are necessary \[[@CR25]\].

A clear distinction could be made between genes that are regulated by P irrespective of the presence of 17β-E2 and genes for which the expression is clearly influenced by the continuous presence of 17β-E~2~. Many genes modulated by P alone were similarly modulated in the 17β-E~2~+P-treated explants (119/161 P-modulated genes), however, 42 of the P-modulated genes were not affected in the 17β-E~2~+P-treated explants. Also, of the 219 17β-E~2~+P-modulated genes, 117 were not modulated by treatment with P alone. This clearly indicates that the expression of a subset of genes is sensitive to the continuing presence of 17β-E~2~. It also indicates that *in vivo* priming of CD12 and CD13 endometrium is remembered by the tissue *in vitro*, leading to similar expression patterns for certain genes induced both in the absence and presence of 17β-E~2~.

A good example of genes for which expression is known to be suppressed by P, but which were only suppressed by P in the presence of 17β-E~2~, are various members of the MMP family \[[@CR12]--[@CR14]\]. Only the expression of MMP11 was suppressed by P alone; the expression of MMP1, −3, −14 and −27 was only suppressed in the presence of 17β-E~2~. Similarly, cystic fibrosis transmembrane conductance regulator (CFTR) was suppressed in 17β-E~2~+P-treated explants but not in P-treated explants, suggesting that continued presence of 17β-E~2~ is required for the down-regulation of CFTR. This corresponds with the finding that CFTR is highly expressed in the human endometrium around the ovulatory period \[[@CR27]\] and is responsive to both 17β-E~2~ and P.

Some genes were induced by 17β-E~2~+P in both menstrual and late proliferative phase explants (i.e. alkaline phosphatase, ALPP; monoamine oxidase, MAOA; secretoglobin family 1, member D, SCGB1D2; CFTR; P450 cytochrome family 26 subfamily A, CYP26A), indicating that the expression of these genes does not depend on prolonged *in vivo* oestrogen priming of the endometrium. Aparticularly interesting observation in this regard is the upregulation of expression of the CYP26A gene in both menstrual and late proliferative phase endometrium by 17β-E~2~+P and, to a lesser extent, by P alone. This enzyme is responsible for the metabolism of the active retinoid metabolite *all*-trans retinoic acid. The importance of controlling retinoid levels in the uterus is illustrated by the fact that vitamin A deficiency in women, nonhuman primates and laboratory animals is associated with pregnancy failure and developmental defects \[[@CR28]--[@CR30]\], whereas excess vitamin A levels are detrimental to blastocyst development \[[@CR31]\] and the decidualization process \[[@CR32]\].

Uterine vitamin A levels in women increase in the presence of oestrogens \[[@CR33], [@CR34]\], most likely as the result of up-regulation of retinaldehyde dehydrogenase (RALDH2), a critical enzyme in retinoic acid (RA) biosynthesis \[[@CR35]\]. Since retinoids are morphogens and essential for epithelial cell growth \[[@CR36]\], they may be involved in the regeneration, growth and differentiation of the endometrial epithelium after menstruation. The induction of CYP26A expression by P in the secretory phase most likely serves to inactivate excessive amounts of retinoids.

Databases can be explored with several different bioinformatics tools. We have employed the Ingenuity Pathways Analysis (IPA) program, which has the added advantage that it is an evidence-based data mining tool. In contrast to most other bioinformatics tools, which annotate certain functions to gene products, the IPA program includes any reported interaction between two genes, whether it involves regulation of gene or protein expression, protein-protein interactions or enzymatic conversion (for example, phosphorylation). It is therefore a continuously growing database and, by the nature of its development, not complete. It is not unusual that the most affected genes are not presented in the networks. The networks present groups of genes that have a proven biological relationship. The nodes in these highly significant networks presumably represent genes that have important modulatory roles. When interpreting the data, one has to realize that the IPA database is biased in that certain genes have received more attention than others and therefore have a higher likelihood to be included in a network. However, the continuously growing database will allow reanalysis of the data in the future, which may reveal novel unidentified relationships between genes or groups of genes.

The significant suppressive actions of P on nodes representing immunomodulators were immediately apparent; these included IL-1β, IL-8, COX2, the chemokine CCL5 and members of the TGF-β super-family (TGF-β2 and -3, INHBA and their signalling molecules SMAD2 and -3). At the end of the secretory phase, a rapid influx of leukocytes, consisting mostly of NK cells and macrophages, into the endometrium can be observed; this is believed to be the result of the disappearance of P suppression on key inflammatory mediators \[[@CR37], [@CR38]\]. Apparently, these immunosuppressive actions of P can at least partly be mimicked in the explant model by short-term incubation with 17β-E~2~ and P.

One of the few nodes present in highly significant networks identified by the IPA program in both 17β-E~2~- and P-treated menstrual and late proliferative phase endometrium was FGF2 or basic fibroblast growth factor (bFGF). FGF2 expression is suppressed by P. The significance of this finding is illustrated by the fact that FGF2 inhibits the decidualization process in human endometrial stromal cells \[[@CR39]\] and should therefore be controlled by P during the secretory phase. FGF2 is an important mitogenic and angiogenic factor that is expressed as different isoforms synthesized through the alternative use of translation initiation codons \[[@CR40]\]. In human endometrium, only the smallest 18-kD isoform is present \[[@CR41]\]. It is located predominantly in the cytoplasm and is stored in the extracellular matrix \[[@CR42]\]. FGF2 is released mostly during menstruation and the early proliferative phase and is expressed in blood vessels throughout the menstrual cycle \[[@CR41], [@CR43]\]. The FGF receptors, however, are not expressed in blood vessels except during the MS (FGFR2) and late secretory phases (FGFR1 and FGFR2). Blood vessels may therefore not be the main target of FGF2. FGF2 receptors are predominantly found in the epithelial compartment \[[@CR44]\], suggesting that FGF2 is involved in the control of regeneration and growth of epithelial cells in a paracrine fashion. FGF2 is known to regulate proliferation of various cell populations of the bone marrow \[[@CR44]\], which were shown to be of eminent importance for regeneration of the human endometrium \[[@CR45]\].

In conclusion, explant culture of human endometrium is a biologically relevant *in vitro* model system that allows the investigation of steroid regulation of gene expression in the tissue context. Regulation of the expression of several genes associated with embryo implantation can be mimicked *in vitro*. We showed that expression of thrombomodulin, monoamine oxidase A and SPARCL1 is regulated by progestins. Only a subset of implantation-associated genes was modulated in the short-term explant cultures; however, we clearly showed that we can distinguish genes that require continuous presence of 17β-E~2~ from those that depend on P only. Therefore, 17β-E~2~ selectively primes implantation-related genes for the effects of P.
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